Malignant mesothelioma patients with germline BAP1 mutations have an overall seven-fold increased long-term survival...
Raleigh, NC (PRWEB) November 13, 2014
Researchers with four major U.S. medical centers have found that mesothelioma patients with a mutation in the tumor suppressor gene BAP1 have an overall median survival of five years, compared to less than a year for patients with sporadic mesothelioma. Click here to read Surviving Mesothelioma’s new article on the research.
Doctors at the University of Hawaii Cancer Center, the Samuel Oschin Comprehensive Cancer Institute-Cedars-Sinai in Los Angeles, the Hofstra-North Shore LIJ School of Medicine in New York, and the New York University Langone Medical Center say the improved mesothelioma survival rates in BAP1 patients held, even in patients who also had a second malignancy.
“In conclusion, we found that malignant mesothelioma patients with germline BAP1 mutations have an overall seven-fold increased long-term survival, independently of sex and age,” writes lead author Dr. Francine Baumann.
The study, published in Carcinogensis, was conducted using patient data from the U.S. SEER cancer database.The team combed through the database of 10,556 U.S. mesothelioma patients between 1973 and 2010 to identify 23 patients with the BAP1 mutation for which there was also survival data.
“Given the poor prognosis for most cases of mesothelioma, this study is potentially very good news for mesothelioma patients with BAP1 mutations, who may be able to take advantage of new and different treatment approaches,” says Alex Strauss, Managing Editor of Surviving Mesothelioma.
For the details of the new study on BAP1 and mesothelioma, see BAP1 Mutation May Bode Well for Mesothelioma Survival now available on the Surviving Mesothelioma website.
Baumann, F, et al, “Mesothelioma Patients with Germline BAP1 Mutations have Seven=Fold Improved Long-term Survival”, November 7, 2014, Carcinogenesis, http://carcin.oxfordjournals.org/content/early/2014/11/06/carcin.bgu227.short?rss=1